Trump's Proposed 200% Tariff Threatens $9.7 Billion Indian Pharma Exports by 2028
Source: ET Real Estate
Arth Insight · What this means for your wallet
- Your investments in Indian pharma companies could see reduced returns if their key US exports are impacted.
- Job opportunities and stability in India's pharmaceutical sector might be affected in the long run.
- A significant hit to India's major export industry could indirectly impact the broader economy and your purchasing power.
Wealth-Impact Simulator
See how a change in interest rates hits your loan EMI.
Indicative estimate for education only — not investment advice.
Compare loan ratesFormer US President Donald Trump's proposed 200% tariff on imported generic drugs could put India's significant $9.7 billion generic drug exports to the United States at risk starting 2028. Indian pharmaceutical companies have a two-year window to explore new markets and adapt, while US patients and insurers may face increased healthcare costs.
- ▸Former US President Donald Trump has proposed a 200% tariff on imported generic drugs.
- ▸This tariff, if implemented from 2028, could risk India's $9.7 billion annual generic drug exports to the US.
- ▸Indian pharmaceutical companies have a two-year period to find new markets and adjust strategies.
- ▸US patients and insurers are expected to face higher healthcare costs due to these tariffs.
- ✓Former US President Donald Trump has proposed a 200% tariff on imported generic drugs.
- ✓This tariff, if implemented from 2028, could risk India's $9.7 billion annual generic drug exports to the US.
- ✓Indian pharmaceutical companies have a two-year period to find new markets and adjust strategies.
- ✓US patients and insurers are expected to face higher healthcare costs due to these tariffs.
A potential 200% tariff on imported generic drugs, proposed by former US President Donald Trump, looms as a significant challenge for India's pharmaceutical industry. This measure, if implemented, could jeopardize Indian generic drug exports to the United States, valued at an estimated $9.7 billion annually.
The proposed tariffs are set to take effect from 2028, providing Indian drugmakers with a crucial two-year lead time. This window offers an opportunity for companies to strategize, explore alternative export markets beyond the US, and adapt their supply chains to mitigate potential impacts.
India is a global leader in generic drug manufacturing, with a substantial portion of its exports heading to the American market. The industry has indicated that 'reshoring' (bringing manufacturing back to the US) is not a practical solution, highlighting the complexities and costs involved in relocating established production facilities.
While the immediate impact on Indian drugmakers is not expected, the long-term implications are considerable. For American patients and insurers, the imposition of such high tariffs would likely translate into significantly increased healthcare costs, making essential generic medicines more expensive.
The announcement underscores the need for Indian pharmaceutical companies to diversify their global footprint and strengthen trade relationships with other nations to reduce reliance on a single major market. The two-year period before 2028 will be critical for the industry to navigate these potential trade policy changes effectively.
This report is for informational purposes only and does not constitute financial advice. Please consult a qualified professional for investment decisions.
Community Pulse · This story
How readers rate the outlook after reading this article. Anonymous · one vote per reader · updates live.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
What is the proposed tariff on generic drugs?
Former US President Donald Trump has proposed a 200% tariff on generic drugs imported into the United States.
How could this tariff impact Indian pharmaceutical companies?
The proposed tariffs could put India's significant $9.7 billion annual generic drug exports to the US at risk from 2028, necessitating Indian firms to seek alternative markets and adapt their strategies.
When would these proposed tariffs take effect?
The proposed tariffs are set to begin in 2028, giving affected companies, including those in India, a two-year window to prepare.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate
Alembic & NATCO Get USFDA Nod for Cancer Drug; Big Market Opportunity
Indian pharmaceutical firms Alembic Pharmaceuticals and NATCO Pharma have received tentative USFDA approval for a generic version of the cancer drug Olaparib. This approval opens up a significant market opportunity in the US, estimated at ₹11,660 crore, though the commercial launch is contingent on ongoing legal proceedings.
Data Center REITs: Should You Invest ₹80,000 in This Growing Digital Infrastructure?
Data centers are emerging as a high-growth asset class within Real Estate Investment Trusts (REITs) due to the global surge in AI and cloud computing. While traditionally a global trend, Indian investors can now explore this sector to diversify their portfolios beyond commercial offices and malls.
Dubai Property Market Hits ₹5.1 Lakh Crore in H1 2026 Despite Regional Tensions
Dubai's residential real estate sector recorded transactions worth AED 225.7 billion (approx. ₹5.1 lakh crore) in the first half of 2026. Despite geopolitical concerns, the market remains a top choice for Indian investors due to strong fundamentals and high demand.
Related Stories
Alembic & NATCO Get USFDA Nod for Cancer Drug; Big Market Opportunity
Indian pharmaceutical firms Alembic Pharmaceuticals and NATCO Pharma have received tentative USFDA approval for a generic version of the cancer drug Olaparib. This approval opens up a significant market opportunity in the US, estimated at ₹11,660 crore, though the commercial launch is contingent on ongoing legal proceedings.
Data Center REITs: Should You Invest ₹80,000 in This Growing Digital Infrastructure?
Data centers are emerging as a high-growth asset class within Real Estate Investment Trusts (REITs) due to the global surge in AI and cloud computing. While traditionally a global trend, Indian investors can now explore this sector to diversify their portfolios beyond commercial offices and malls.
Dubai Property Market Hits ₹5.1 Lakh Crore in H1 2026 Despite Regional Tensions
Dubai's residential real estate sector recorded transactions worth AED 225.7 billion (approx. ₹5.1 lakh crore) in the first half of 2026. Despite geopolitical concerns, the market remains a top choice for Indian investors due to strong fundamentals and high demand.
Is Real Estate Still a Smart Investment for Indians? A Look Beyond Traditional Returns
The perception of real estate as a guaranteed wealth builder is shifting, prompting a re-evaluation of its role in an investment portfolio. While it may not offer the rapid appreciation seen in previous decades, real estate can still be a valuable asset for Indian investors, particularly when considering long-term goals and diversification.